




Instance: composition-en-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: CompositionUvEpi
Title: "Composition for incresync Package Leaflet"
Description:  "Composition for incresync Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/842/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - incresync"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Incresync is and what it is used for </li>
<li>What you need to know before you take Incresync</li>
<li>How to take Incresync</li>
<li>Possible side effects </li>
<li>How to store Incresync</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What incresync is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What incresync is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Incresync is
Incresync contains two different medicines called alogliptin and pioglitazone in one tablet:
-
alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 
inhibitors). Alogliptin works to increase the levels of insulin in the body after a meal and 
decrease the amount of sugar in the body. 
-
pioglitazone belongs to a group of medicines called thiazolidinediones. It helps your body make 
better use of the insulin it produces.
Both of these groups of medicines are  oral anti-diabetics .
What Incresync is used for
Incresync is used to lower blood sugar levels in adults with type 2 diabetes. Type 2 diabetes is also 
called non-insulin-dependent diabetes mellitus or NIDDM.
Incresync is taken when your blood sugar cannot be adequately controlled by diet, exercise and other 
oral anti-diabetic medicines such as pioglitazone; or pioglitazone and metformin taken together. Your 
doctor will check whether Incresync is working 3 to 6 months after you start taking it.
If you are already taking both alogliptin and pioglitazone as single tablets, Incresync can replace them 
in one tablet.
It is important that you continue to follow the advice on diet and exercise that your nurse or doctor has 
given you.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take Incresync</h2>
<p>if you are allergic to alogliptin, pioglitazone or any of the other ingredients of this medicine 
(listed in section 6).
-
if you have had a serious allergic reaction to any other similar medicines that you take to control 
your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised red patches 
on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in 
breathing or swallowing. Additional symptoms may include general itching and feeling of heat 
especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson 
syndrome).
-
if you have heart failure or have had heart failure in the past.
-
if you have liver disease.
-
if you have diabetic ketoacidosis (a serious complication of poorly controlled diabetes). 
Symptoms include excessive thirst, frequent urination, loss of appetite, nausea or vomiting and 
rapid weight loss.
-
if you have or have ever had bladder cancer.
-
if you have blood in your urine that your doctor has not checked. Do not take Incresync and get 
your doctor to check your urine as soon as possible. 
Warnings and precautions 
Talk to your doctor or pharmacist before taking Incresync:
-
if you have type 1 diabetes (your body does not produce insulin).
-
if you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, 
glibenclamide) or insulin. 
-
if you suffer from heart disease or fluid retention. If you take anti-inflammatory medicines 
which can also cause fluid retention and swelling, you must also tell your doctor.
-
if you are elderly and are taking insulin, because you may have an increased risk of heart 
problems.
-
if you have a problem with your liver or kidneys. Before you start taking this medicine you will 
have a blood sample taken to check your liver and kidney function. This check may be repeated 
at intervals. In case of kidney disease, your doctor may reduce the dose of Incresync.
-
if you have a special type of diabetic eye disease called macular oedema (swelling of the back 
of the eye).
-
if you have cysts on your ovaries (polycystic ovarian syndrome). There may be an increased 
possibility of becoming pregnant because you may ovulate again when you take Incresync. If 
this applies to you, use appropriate contraception to avoid the possibility of an unplanned 
pregnancy.
-
if you have or have had a disease of the pancreas.
Slight changes in cell counts may show up in blood tests. Your doctor may discuss the results with 
you. 
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your 
doctor will take this into account when treating your diabetes.
Contact your doctor if you encounter blistering of the skin, as it may be a sign for a condition called 
bullous pemphigoid. Your doctor may ask you to stop alogliptin.
Children and adolescents
Incresync is not recommended for children and adolescents under 18 years due to the lack of data in 
these patients. 
Other medicines and Incresync
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. 
In particular tell your doctor or pharmacist if you are taking any of the following:
-
gemfibrozil (used to lower cholesterol)
-
rifampicin (used to treat tuberculosis and other infections) 
Your blood sugar will be checked and your dose of Incresync may need to be changed.
Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. 
There is no experience of using Incresync in pregnant women or during breast-feeding. Incresync 
should not be used during pregnancy or breast-feeding. 
Driving and using machines
You may experience visual disturbances while taking this medicine. If this happens, do not drive or 
use any tools or machines. Taking Incresync in combination with other anti-diabetic medicines can 
cause low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use 
machines.
Incresync contains lactose 
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor 
before taking Incresync.
Incresync contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free .</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.
Your doctor will tell you how much Incresync you need to take and if you need to change the amount 
of other medicines you take.
The maximum recommended daily dose is one 25 mg/45 mg tablet.
Incresync should be taken once daily. Swallow your tablet(s) whole with water. You can take this 
medicine with or without food.
If you have kidney problems your doctor may prescribe you a reduced dose.
If you are following a diabetic diet, you should continue with this while you are taking Incresync.
Your weight should be checked at regular intervals; if your weight increases, tell your doctor. 
If you take more Incresync than you should
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or 
go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that 
your doctor knows exactly what you have taken. 
If you forget to take Incresync
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up 
for a forgotten dose.
If you stop taking Incresync
Do not stop taking Incresync without consulting your doctor first. Your blood sugar levels may 
increase when you stop taking Incresync.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Incresync and contact a doctor immediately if you notice any of the following
serious side effects:
Common (may affect up to 1 in 10 people):
-
Sudden and severe bone pain or immobility (particularly in women). 
Uncommon (may affect up to 1 in 100 people):
-
Symptoms of bladder cancer including blood in your urine, pain when urinating or a sudden 
need to urinate.
Not known (frequency cannot be estimated from the available data):
-
An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing 
problems, swelling of your lips, face, throat or tongue and feeling faint. 
-
A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore 
surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms 
such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy 
eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme). 
-
Severe and persistent pain in the abdomen (stomach area) which might reach through to your 
back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas 
(pancreatitis). 
You should also discuss with your doctor if you experience the following side effects:
Common:
-
Symptoms of low blood sugar (hypoglycaemia) may occur when Incresync is taken in 
combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). 
Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, 
mood change or feeling confused. Your blood sugar could fall below the normal level, but can 
be increased again by taking sugar. It is recommended that you carry some sugar lumps, sweets, 
biscuits or sugary fruit juice.
-
Cold or flu-like symptoms such as sore throat, stuffy or blocked nose
-
Inflammation of the sinuses (sinusitis)
-
Itchy skin
-
Headache
-
Stomach ache
-
Diarrhoea
-
Indigestion, heartburn
-
Feeling sick
-
Muscle pain
-
Feeling numb in any part of your body
-
Blurred or distorted vision
-
Weight gain
-
Swollen or puffy hands or feet
-
Rash
Uncommon:
-
Difficulty sleeping
Not known:
-
Visual disturbances (caused by a condition called macular oedema).
-
Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, 
loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.
-
Inflammation of the connective tissue within the kidneys (interstitial nephritis).
-
Blistering of the skin (bullous pemphigoid).
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Store in the 
original package in order to protect from moisture.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Incresync contains</h2>
<p>The active substances are alogliptin and pioglitazone.
Each 25 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride 
equivalent to 25 mg alogliptin and 30 mg pioglitazone.
-
The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, 
croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium 
dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac and 
black iron oxide (E172). See section 2  Incresync contains lactose .
Each 25 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride 
equivalent to 25 mg alogliptin and 45 mg pioglitazone.
-
The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, 
croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium 
dioxide (E171), red iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172). See 
section 2  Incresync contains lactose .
Each12.5 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride 
equivalent to 12.5 mg alogliptin and 30 mg pioglitazone.
-
The other ingredients are mannitol, microcrystalline cellulose, hydroxypropylcellulose, 
croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, talc, titanium 
dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac, 
carnauba wax and glycerol mono-oleate. See section 2  Incresync contains lactose .
What Incresync looks like and contents of the pack
-
Incresync 25 mg/30 mg film-coated tablets (tablets) are peach, round (approximately 8.7 mm in 
diameter), biconvex, film-coated tablets, with both  A/P  and  25/30  printed in grey ink on 
one side.
-
Incresync 25 mg/45 mg film-coated tablets (tablets) are red, round (approximately 8.7 mm in 
diameter), biconvex, film-coated tablets, with both  A/P  and  25/45  printed in grey ink on 
one side.
-
Incresync 12.5 mg/30 mg film-coated tablets (tablets) are pale peach, round (approximately 
8.7 mm in diameter), biconvex, film-coated tablets, with both  A/P  and  12.5/30  printed in 
red ink on one side.
Incresync is available in blister packs containing 10, 14, 28, 30, 56, 60, 90, 98 or 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Takeda Pharma A/S
Delta Park 2665 Vallensbaek Strand
Denmark
Manufacturer
Takeda Ireland Limited
Bray Business Park
Kilruddery
Co. Wicklow
Ireland
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com
Luxembourg/Luxemburg
Takeda Belgium NV
Tel/T l: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
Takeda HELLAS S.A.
Tel: +30 210 6387medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>Takeda    . .
 : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges. m.b.H.
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com 
Espa a
Laboratorios Menarini, S.A
Tel: +34 934 628 info@menarini.es
Polska
Takeda Pharma Sp. z o.o.
tel: +48223062medinfoEMEA@takeda.com 
France
Takeda France SAS
Tel: + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Tecnimede - Sociedade T cnico-Medicinal, S.A 
Tel: +351 21 041 41 dmed.fv@tecnimede.pt 
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o..
Tel: +386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>Takeda    . .
 : +30 210 6387medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in 
Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: CompositionUvEpi
Title: "Composition for incresync Package Leaflet"
Description:  "Composition for incresync Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/842/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - incresync"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Incresync
3. Sådan skal du tage Incresync
4. Bivirkninger 
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger.</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Incresync er
Incresync indeholder to forskellige lægemidler, alogliptin og pioglitazon, i én tablet:
-
alogliptin tilhører en gruppe af lægemidler, der kaldes DPP-4-hæmmere 
(dipeptidyl peptidase-4-hæmmere). Alogliptin virker ved at øge insulinniveauet i kroppen efter 
et måltid og sænke mængden af sukker i kroppen. 
-
pioglitazon tilhører en gruppe af lægemidler, der kaldes thiazolidindioner. Pioglitazon hjælper 
din krop med bedre at udnytte den insulin, den producerer.
Begge disse grupper af lægemidler er såkaldte orale antidiabetika (diabetesmedicin til at indtage 
gennem munden).
Hvad Incresync bruges til
Incresync sænker blodsukkeret hos voksne med type 2-diabetes. Type 2-diabetes kaldes også 
ikke-insulinkrævende diabetes mellitus eller gammelmandssukkersyge.
Du kan tage Incresync, hvis dit blodsukker ikke kan styres godt nok gennem kost, motion og andre 
orale antidiabetika såsom pioglitazon eller pioglitazon og metformin taget samtidigt. Din læge tjekker, 
om Incresync virker tilfredsstillende, 3 til 6 måneder efter du er startet med at tage det.
Hvis du allerede tager både alogliptin og pioglitazon som separate tabletter, kan Incresync erstatte dem 
begge.
Det er vigtigt, at du bliver ved med at følge de råd om kost og motion, som din læge eller 
sygeplejerske har givet dig.
44</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Incresync</h2>
<p>hvis du er allergisk over for alogliptin, pioglitazon eller et af de øvrige indholdsstoffer i 
Incresync (angivet i punkt 6).
-
hvis du har haft en alvorlig allergisk reaktion over for andre lignende lægemidler, som du tager 
for at styre dit blodsukker. Tegn på en alvorlig allergisk reaktion kan være udslæt, hævede røde 
områder på huden (nældefeber) og hævelse af ansigt, læber, tunge eller svælg, som kan gøre det 
svært for dig at trække vejret eller synke. De tegn, du skal være opmærksom på, er kløe, en 
følelse af varme især i hovedbund, mund, hals, håndflader og fodsåler (Stevens-Johnsons 
syndrom).
-
hvis du lider af hjertesvigt eller tidligere har haft hjertesvigt.
-
hvis du har en leversygdom.
-
hvis du lider af diabetisk ketoacidose (en alvorlig komplikation ved dårligt reguleret diabetes). 
De symptomer, du skal være opmærksom på, er udtalt tørst, hyppig vandladning, appetitløshed, 
kvalme eller opkastning og hurtigt vægttab.
-
hvis du lider af eller tidligere har haft blærecancer.
-
hvis du har blod i urinen, som din læge ikke har undersøgt. Undlad at tage Incresync, og få din 
læge til at tjekke din urin hurtigst muligt. 
Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Incresync:
-
hvis du har type 1-diabetes (din krop kan ikke producere insulin).
-
hvis du tager diabetesmedicin af typen sulfonylurinstof (f.eks. glipizid, tolbutamid, 
glibenclamid) eller insulin. 
-
hvis du lider af en hjertesygdom eller af væskeophobning. Hvis du tager antiinflammatorisk 
medicin, som også kan forårsage væskeophobning og hævelse, skal du også fortælle din læge 
det.
-
hvis du er ældre og tager insulin, fordi du kan have en øget risiko for hjerteproblemer.
-
hvis du har problemer med lever eller nyrer. Før du begynder at tage Incresync, vil du få taget 
en blodprøve til kontrol af lever- og nyrefunktion. Denne kontrol skal måske udføres løbende. 
Hvis du har en nyresygdom, vil din læge muligvis nedsætte dosen af Incresync.
-
hvis du lider af en særlig diabetisk øjenlidelse, som hedder makulaødem (væskeansamling i det 
bagerste af øjet).
-
hvis du har cyster på æggestokkene (polycystisk ovariesyndrom). Der kan være større 
sandsynlighed for at blive gravid, fordi du kan få ægløsning igen, når du tager Incresync. Hvis 
dette er relevant for dig, skal du anvende sikker prævention, så du undgår uønsket graviditet.
-
hvis du har eller har haft sygdom i bugspytkirtlen.
Blodprøverne kan vise små ændringer i dine blodværdier. Din læge vil muligvis tale med dig om det. 
Der er set et øget antal knoglebrud hos patienter, især kvinder, der tager pioglitazon. Din læge vil tage 
dette i betragtning ved planlægning af din behandling.
Kontakt lægen, hvis du får blærer på huden, da det kan være tegn på en sygdom, der hedder bulløs 
pemfigoid. Din læge vil muligvis bede dig om at holde op med at tage alogliptin.
Børn og unge
Incresync anbefales ikke til børn og unge under 18 år, da der ikke foreligger tilstrækkelige data for 
denne aldersgruppe. 
Brug af anden medicin sammen med Incresync
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin for, nylig har taget
anden medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke er købt på 
recept, f.eks. naturlægemidler og vitaminer og mineraler.
45
Det er især vigtigt, at du fortæller det til lægen, hvis du i forvejen tager et af disse lægemidler:
-
gemfibrozil (bruges til at sænke kolesterol)
-
rifampicin (bruges til at behandle tuberkulose og andre infektionssygdomme). 
Du vil få kontrolleret blodsukkeret for at se, om du skal have ændret doseringen af Incresync.
Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. 
Der er ingen erfaringer med brug af Incresync til gravide eller ammende kvinder. Du må ikke tage 
Incresync, hvis du er gravid eller ammer. 
Trafik- og arbejdssikkerhed
Du kan opleve synsforstyrrelser, når du tager Incresync. Hvis dette sker, må du ikke køre bil eller 
betjene værktøj eller maskiner. Hvis du tager Incresync samtidig med anden diabetesmedicin, kan du 
få for lavt blodsukker (hypoglykæmi), hvilket kan påvirke din evne til at køre bil og betjene maskiner.
Incresync indeholder lactose
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke kan tåle visse 
sukkerarter.
Incresync indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens, eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen, eller apotekspersonalet.
Lægen fortæller dig, hvor meget Incresync du skal tage, og om du skal ændre mængden af andre 
lægemidler, du tager.
Den højeste anbefalede dosis er én 25 mg/45 mg-tablet dagligt.
Incresync skal tages én gang dagligt. Synk tabletten hel sammen med vand. Du kan tage Incresync 
med eller uden et måltid.
Hvis du har nyreproblemer, vil din læge muligvis ordinere en lavere dosis til dig.
Hvis du følger en diabetesdiæt, skal du fortsætte med denne, mens du tager Incresync.
Din vægt bør tjekkes med jævne mellemrum, og hvis den stiger, skal du kontakte din læge. 
Hvis du har taget for meget Incresync
Hvis du har taget flere tabletter, end du skulle, eller hvis en anden person, f.eks. et barn, tager dine 
tabletter, skal du kontakte læge eller søge til den nærmeste skadestue med det samme. Tag denne 
indlægsseddel eller nogle tabletter med, så lægen nøjagtigt ved, hvad der er indtaget.
Hvis du har glemt at tage Incresync
Hvis du har glemt at tage en dosis, skal du tage den så snart, du kommer i tanke om det. Du må ikke 
tage en dobbeltdosis som erstatning for den glemte dosis.
46
Hvis du holder op med at tage Incresync
Hold ikke op med at tage Incresync uden at tale med din læge først. Dit blodsukker kan blive højere, 
når du holder op med at tage Incresync.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
STOP med at tage Incresync, og kontakt lægen med det samme, hvis du får en eller flere af de 
følgende alvorlige bivirkninger:
Almindelige bivirkninger (forekommer hos op til 1 ud af 10 personer):
-
Pludselige og stærke knoglesmerter eller ubevægelighed (særligt hos kvinder).
Ikke almindelige bivirkninger (forekommer hos op til 1 ud af 100 personer):
-
Symptomer på blærecancer, herunder blod i urinen, smerter ved vandladning og pludselig 
vandladningstrang.
Bivirkninger med ukendt hyppighed (hyppigheden kan ikke bestemmes ud fra de foreliggende
data):
-
En allergisk reaktion. Tegnene kan være udslæt, nældefeber, synke- eller åndedrætsbesvær, 
opsvulmede læber, ansigt, svælg eller tunge og besvimelsesfornemmelse. 
-
En alvorlig allergisk reaktion: hudlæsioner eller pletter på huden, der kan udvikle sig til et sår 
omgivet af blege eller røde ringe, blæredannelse og/eller afskalning af huden eventuelt med 
symptomer som kløe, feber, generel utilpashed, smertende led, synsforstyrrelser, brændende 
smertefuld eller kløende øjne og sår i munden (Steven-Johnson syndrome og erythema 
multiforme).
-
Stærke og vedvarende smerter i maven, som kan stråle ud i ryggen, samt kvalme og 
opkastning. Det kan være tegn på betændelse i bugspytkirtlen (pancreatitis).
Du skal også fortælle din læge, hvis du får følgende bivirkninger: 
Almindelige bivirkninger:
-
Tegn på lavt blodsukker (hypoglykæmi), som kan opstå, hvis Incresync tages i kombination 
med insulin eller sulfonylurinstof (f.eks. glipizid, tolbutamid eller glibenclamid). Tegnene kan 
være rysten, svedtendens, angst, sløret syn, prikkende fornemmelse i læber, bleghed, 
humørsvingninger eller forvirring. Blodsukkeret kan falde til under det normale niveau, men kan 
bringes til at stige igen, hvis du indtager sukker. Det anbefales, at du altid medbringer lidt 
sukkerknalder, slik, kiks eller sukkerholdig frugtjuice.
-
forkølelse eller influenzalignende symptomer som ondt i halsen og tilstoppet næse
-
bihulebetændelse (sinusitis)
-
hudkløe
-
hovedpine
-
mavesmerter
-
diarré 
-
fordøjelsesbesvær, opstød 
-
almen sygdomsfornemmelse
-
muskelsmerter
-
følelsesløshed i en del af kroppen
-
sløret eller forvrænget syn
-
vægtforøgelse
-
hævede hænder eller fødder
-
udslæt
47
Ikke almindelige bivirkninger:
-
søvnbesvær
Bivirkninger med ukendt hyppighed: 
-
synsforstyrrelser (forårsaget af en diabetisk øjenlidelse kaldet makulaødem)
-
leverproblemer, der viser sig som kvalme, opkastning, mavesmerter, usædvanlig eller 
uforklarlig træthed, manglende appetit, mørkfarvet urin eller gulfarvning af huden eller det 
hvide i øjnene
-
betændelse i bindevævet i nyrerne (interstitiel nefritis)
-
blærer på huden (bulløs pemfigoid).
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke Incresync efter den udløbsdato, der står på æsken og blisterkortet efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned.
Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares i den 
originale yderpakning for at beskytte mod fugt.
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Incresync indeholder:</h2>
<p>Aktive stoffer: alogliptin og pioglitazon.
Hver 25 mg/30 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid
svarende til 25 mg alogliptin og 30 mg pioglitazon.
-
Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, 
croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, 
titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac, og sort 
jernoxid (E172). Se punkt 2 "Incresync indeholder lactose".
Hver 25 mg/45 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid
svarende til 25 mg alogliptin og 45 mg pioglitazon.
-
Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, 
croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, 
titandioxid (E171), rød jernoxid (E172), macrogol 8000, shellac, og sort jernoxid (E172). Se 
punkt 2 "Incresync indeholder lactose".
Hver 12,5 mg/30 mg filmovertrukken tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid
svarende til 12,5 mg alogliptin og 30 mg pioglitazon.
-
Øvrige indholdsstoffer: mannitol, mikrokrystallinsk cellulose, hydroxypropylcellulose, 
croscarmelosenatrium, magnesiumstearat, lactosemonohydrat, hypromellose, talkum, 
titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac, 
carnaubavoks og glycerol mono-oleat. Se punkt 2 "Incresync indeholder lactose".
48
Udseende og pakningstørrelser
-
Incresync 25 mg/30 mg filmovertrukne tabletter (tabletter) er ferskenfarvede, runde (ca. 8,7 mm 
i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"25/30" trykt i gråt på den 
ene side.
-
Incresync 25 mg/45 mg filmovertrukne tabletter (tabletter) er røde, runde (ca. 8,7 mm i 
diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"25/45" trykt i gråt på den 
ene side.
-
Incresync 12,5 mg/30 mg filmovertrukne tabletter (tabletter) er svagt ferskenfarvede, runde (ca. 
8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P" og"12.5/30" trykt i 
rødt på den ene side.
Incresync fås i blisterpakninger indeholdende 10, 14, 28, 30, 56, 60, 90, 98 eller 100 tabletter.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
Takeda Pharma A/S
Delta Park 45
2665 Vallensbæk Strand
Danmark
Fremstiller
Takeda Ireland Limited
Bray Business Park
Kilruddery
Co. Wicklow
Irland
Hvis du ønsker yderligere oplysninger om Incresync, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Takeda Belgium NV
Tel/Tél: +32 2 464 06 11
medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com
България
Такеда България ЕООД
Тел.: +359 2 958 27 36
medinfoEMEA@takeda.com
Luxembourg/Luxemburg
Takeda Belgium NV
Tel/Tél: +32 2 464 06 11
medinfoEMEA@takeda.com
Česká republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com
Magyarország
Takeda Pharma Kft.
Tel: +36 1 270 7030
medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 10
medinfoEMEA@takeda.com
Malta
Takeda HELLAS S.A.
Tel: +30 210 6387800
medinfoEMEA@takeda.com
49
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 669
medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com
Ελλάδα
Takeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com
Österreich
Takeda Pharma Ges. m.b.H.
Tel: +43 (0) 800-20 80 50
medinfoEMEA@takeda.com 
España
Laboratorios Menarini, S.A
Tel: +34 934 628 800
info@menarini.es
Polska
Takeda Pharma Sp. z o.o.
tel: +48223062447
medinfoEMEA@takeda.com 
France
Takeda France SAS
Tel: + 33 1 40 67 33 00
medinfoEMEA@takeda.com
Portugal
Tecnimede - Sociedade Técnico-Medicinal, S.A 
Tel: +351 21 041 41 dmed.fv@tecnimede.pt 
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com
România
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska družba d.o.o..
Tel: +386 (0) 59 082 480
medinfoEMEA@takeda.com
Ísland
Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com
Slovenská republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com
Κύπρος
Takeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840082
medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 902
medinfoEMEA@takeda.com
50
Denne indlægsseddel blev senest ændret 
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for incresync Package Leaflet for language en"
Description: "ePI document Bundle for incresync Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9cd7665100fd3b81b318cbcb65d45fef"
* entry[0].resource = composition-en-9cd7665100fd3b81b318cbcb65d45fef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9cd7665100fd3b81b318cbcb65d45fef"
* entry[=].resource = mp9cd7665100fd3b81b318cbcb65d45fef
                            
                    
Instance: bundlepackageleaflet-da-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for incresync Package Leaflet for language da"
Description: "ePI document Bundle for incresync Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9cd7665100fd3b81b318cbcb65d45fef"
* entry[0].resource = composition-da-9cd7665100fd3b81b318cbcb65d45fef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9cd7665100fd3b81b318cbcb65d45fef"
* entry[=].resource = mp9cd7665100fd3b81b318cbcb65d45fef
                            
                    



Instance: mp9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Incresync 12.5 mg/30 mg film-coated tablets"
Description: "Incresync 12.5 mg/30 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/842/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Incresync 12.5 mg/30 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9cd7665100fd3b81b318cbcb65d45fefListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "incresync"

* status = #current
* mode = #working

* title = "List of all ePIs associated with incresync"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#incresync "incresync"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9cd7665100fd3b81b318cbcb65d45fef) // incresync en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9cd7665100fd3b81b318cbcb65d45fef) // incresync da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: List

* insert 9cd7665100fd3b81b318cbcb65d45fefListRuleset
    